MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

SpringWorks Therapeutics Inc

Gesloten

SectorGezondheidszorg

46.51 11.53

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

41.08

Max

46.89

Belangrijke statistieken

By Trading Economics

Inkomsten

-24M

-77M

Verkoop

12M

62M

EPS

-1.04

Winstmarge

-125.586

Werknemers

368

EBITDA

-23M

-80M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+71.23% upside

Dividenden

By Dow Jones

Volgende Winsten

1 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-839M

3.3B

Vorige openingsprijs

34.98

Vorige sluitingsprijs

46.51

Nieuwssentiment

By Acuity

50%

50%

180 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

SpringWorks Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 feb 2025, 07:03 UTC

Acquisities, Fusies, Overnames

Germany's Merck in Talks to Buy SpringWorks Therapeutics

10 feb 2025, 16:38 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

11 feb 2025, 10:54 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

11 feb 2025, 10:52 UTC

Marktinformatie
Acquisities, Fusies, Overnames

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Peer Vergelijking

Prijswijziging

SpringWorks Therapeutics Inc Prognose

Koersdoel

By TipRanks

71.23% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 71.71 USD  71.23%

Hoogste 87 USD

Laagste 63 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor SpringWorks Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technische score

By Trading Central

44.13 / 47.505Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

180 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.